Introduction {#s1}
============

Hypothyroidism is a prevalent condition, diagnosed in most cases by an elevation in serum TSH ([@B1]). While severe myxedema has been clinically recognized since the nineteenth century, the diagnosis of lower-grade hypothyroidism has not always been straightforward ([@B2]); early diagnostic attempts relied on parameters such as a slow basal metabolic rate (BMR), low serum protein-bound iodine (PBI), or even clinical responsiveness to thyroid preparations ([@B3]). In patients for whom the diagnosis has been secured, thyroid hormone replacement has been the mainstay of therapy for over a century ([@B1], [@B3]). Natural thyroid preparations, i.e., thyroid extract, desiccated thyroid, or thyroglobulin, were the first pharmacologic treatments while synthetic agents were introduced later and are the standard of care today ([@B3]). Despite major progress, there remains debate as to whether a universal approach is applicable to all patients and which agent constitutes the best thyroid hormone replacement.

Combination therapy via natural thyroid preparations remained the dominant therapeutic option for the better part of the twentieth century; dosages were adjusted to resolve symptoms and to normalize BMR/PBI ([@B4]--[@B6]). Yet with this regimen, thyrotoxic side effects were not uncommon ([@B7]). In the 1970\'s, the clinical approach to the hypothyroid patient changed markedly based on (i) the development of immunological assays to measure serum TSH as a more reliable biochemical index of thyroid activity ([@B8]), (ii) the accessible pricing of synthetic thyroid hormone formulations, and (iii) the discovery that in humans most circulating T3 is derived via extrathyroidal conversion of T4 ([@B3], [@B9]). These three factors led to a dramatic change in how hypothyroidism was diagnosed and treated, such that in the last 40 years (i) measurement of serum TSH has become the cornerstone of diagnosis and therapeutic monitoring, (ii) the replacement dosage of thyroid hormone has been substantially decreased, and (iii) "monotherapy" with levothyroxine (LT4) has become a universally accepted first-line approach given its excellent safety index. LT4 monotherapy establishes normalization of serum TSH levels and symptomatic remission for a majority of patients. Of course, the foundation for the success of this regimen is largely attributed to the physiologic action of the deiodinases ([@B10]); it is widely accepted that LT4 restores the pool of prohormone, T4, and the deiodinases regulate peripheral T3 production ([@B11]).

The efficacy of LT4 monotherapy has come into question as with this approach, 10--15% of patients express dissatisfaction due to residual symptoms of hypothyroidism ([@B12], [@B13]), and specifically cognitive impairment ([@B14], [@B15]). This might not have happened in the previous era given the much higher replacement doses of thyroid hormone used prior to the institution of the serum TSH radioimmunoassay (RIA) ([@B3]). In fact, when the dose of LT4 is adjusted to maintain a normal serum TSH, the ability of the deiodinases to appropriately regulate T3 availability has been challenged by the observation that about 15% of patients receiving LT4 alone fail to achieve normal serum T3 levels ([@B15]--[@B17]). The study of a number of animal models indicate that maintaining normal serum T3 levels is a biological priority ([@B18]). Although the clinical significance of relatively low serum T3 is not well-defined ([@B1]), there is evidence demonstrating that elevating serum T3 utilizing combination therapy can have improved symptomatology for some patients ([@B19]--[@B22]). Thus, given the high prevalence of hypothyroidism and the significant proportion of patients that remain symptomatic, this represents a target for improvement of the public health. The most recent treatment guidelines have been revised to acknowledge these gaps in the approach to hypothyroid patients ([Table 1](#T1){ref-type="table"}) ([@B1], [@B26], [@B27]).

###### 

Trends in guidelines from professional societies.

  **Authors (year)**          **Professional Society**   **Rec \#**   **Standard of care**                                                                                                                                                                                           **Notes about combination therapy**                                                                                                                                                                                                                                                                                                                                                                                          **Goal**
  --------------------------- -------------------------- ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Singer et al. ([@B23])      ATA                                     LT4 "is the treatment of choice for the routine management of hypothyroidism"                                                                                                                                  Chronic LT3 "not recommended"DT "not necessarily contraindicated"                                                                                                                                                                                                                                                                                                                                                            Normalization of serum TSH
  Baskin et al. ([@B24])      AACE/ATA                                "all physicians will treat clinical hypothyroidism with" LT4                                                                                                                                                   "desiccated thyroid hormone, combinations of thyroid hormones, or triiodothyronine should not be used as replacement therapy""insufficient evidence is available to know which patients with hypothyroidism, if any, would be better treated with a combination of T4 plus T3 rather than with T4 alone"                                                                                                                     Normalization of serum TSH
  Garber et al. ([@B25])      AACE/ATA                   22.1         "Patients with hypothyroidism should be treated with L-thyroxine monotherapy"                                                                                                                                  REC 22.2: "The evidence does not support using L-thyroxine and L-triiodothyronine combinations to treat hypothyroidism."REC 22.4: "There is no evidence to support using desiccated thyroid hormone in preference to L-thyroxine monotherapy in the treatment of hypothyroidism and therefore desiccated thyroid hormone should not be used for the treatment of hypothyroidism."                                            Normalization of serum TSH
  Wiersinga et al. ([@B26])   ETA                        1, 2         Acknowledgment that some LT4-treated patients with normal serum TSH may have persistent symptoms                                                                                                               Rec 7: "L-T4 + L-T3 combination therapy might be considered as an experimental approach in compliant L-T4-treated hypothyroid patients who have persistent complaints despite serum TSH values within the reference range"                                                                                                                                                                                                   "The goal of...combination therapy is to resolve persistent complaints despite a normal TSH in L-T4-treated hypothyroid patients. In an attempt to realize this goal, it is assumed that...a euthyroid state simultaneously in all tissues of hypothyroid patients is present if serum TSH, free T4, free T3, and free T4:free T3 ratio are all within the reference range."
  Jonklaas et al. ([@B1])     ATA                        1a           "Levothyroxine is recommended as the preparation of choice for the treatment of hypothyroidism"                                                                                                                Rec 13c: "For patients with primary hypothyroidism who feel unwell on levothyroxine therapy alone...there is currently insufficient evidence to support the routine use of a trial of a combination of levothyroxine and liothyronine therapy...due to uncertainty in long-term risk benefit ratio of the treatment and uncertainty as to the optimal definition of a successful trial to guide clinical decision-making."   Rec 1b: LT4 treatment goals include "(i) to provide resolution of the patients\' symptoms and hypothyroid signs, including biological and physiologic markers of hypothyroidism, (ii) to achieve normalization of serum thyrotropin with improvement in thyroid hormone concentrations"
  Okosieme et al. ([@B27])    BTF                        5            "L-T4 remains the treatment of choice in hypothyroidism with the aim of therapy being to restore physical and psychological well-being while maintaining normal laboratory reference range serum TSH levels"   Rec 10: "L-T4/L-T3 combination therapy in patients with hypothyroidism should not be used routinely"Rec 12: "If a decision is made to embark on a trial of L-T4/L-T3 combination therapy in patients who have unambiguously not benefited from L-T4, then this should be reached following an open and balanced discussion of the uncertain benefits, likely risks of over-replacement and lack of long-term safety data."   Normalization of serum TSH

*AACE, American Academy of Clinical Endocrinologists; ATA, American Thyroid Association; BTF, British Thyroid Association; ETA, European Thyroid Association; LT4/L-T4, levothyroxine; LT3/L-T3, liothyronine; DT, desiccated thyroid; TSH, thyroid-stimulating hormone*.

There are new insights into the molecular mechanisms underlying the relatively lower serum T3 associated with LT4 monotherapy ([@B28]), namely that the hypothalamus exhibits altered D2 ubiquitination, explaining the inability of LT4 alone to normalize serum T3 levels ([@B29]). Only steady delivery of LT4 and LT3 in thyroidectomized rats fully normalizes serum and tissue T3 levels ([@B30]), as well as T3-dependent metabolic markers and gene expression profiles in this animal model ([@B29]). In humans, a large systematic review and meta-analysis recently showed that T3-dependent metabolic markers, such as total and LDL cholesterol, remain significantly higher in LT4-treated hypothyroid patients with normal serum TSH levels compared to healthy controls ([@B31]). A prevalent genetic polymorphism in the type 2 deiodinase, Thr92AlaD2, disrupts cellular morphology, has a prolonged half-life, is associated with ER stress and may exhibit decreased catalytic activity ([@B32]--[@B34]). Although further studies are needed to confirm these mechanisms and the clinical implications of a relatively low serum T3 need to be further defined, the available clinical evidence suggest that LT4 monotherapy may not represent a universal "replacement" for endogenous euthyroidism.

Need for Thyroid Replacement Established, Treatment Strategies Refined {#s2}
======================================================================

Cases describing the clinical syndromes resulting from severe hypothyroidism, namely cretinism in children and myxedema in adults, were reported in the mid-nineteenth century ([@B35]--[@B38]) but were not initially connected with a deficiency from the thyroid gland ([@B35], [@B39]). The causal relationship was not understood until surgeons noted incident myxedema following total thyroidectomy ([@B40], [@B41]); milder symptoms consisting of a "*dull, listless, mental state*" were noted when only partial thyroidectomy was performed ([@B42]). By the late 1890\'s, its clinical features were well-described and its epidemiology better understood; myxedema could be sporadic, of insidious onset, occurred more commonly in women, and its prevalence variable by region ([@B43]).

Initial treatment strategies for hypothyroidism were largely insufficient, basically supportive and symptom-directed therapies: "*protection against cold, persistent use of hot baths with vigorous friction did much good;...The more favorable surroundings in hospital conferred temporary benefit on some cases, and removal to a mild and genial climate on others*" ([@B44]). The significant morbidity and mortality in the absence of efficacious treatment was clear, "*the progress of the disease is not readily affected by any remedy. The prognosis is altogether unfavorable*," ([@B45]) and thus the need to "replace" the thyroid was established. Thyroid transplant ([@B46]--[@B50]), seemingly the most divergent from contemporary approaches, had some early successes as many patients had improvement after receiving animal (sheep or goat, preferably pregnant) or human thyroid glands taken from patients with Graves\' disease or goiter. Grafts were typically transplanted into the tibia or the abdominal cavity. For many patients, symptoms recurred and the procedure was repeated in some up to four times ([@B51]). Due to the rapid and transient improvement observed, "*too soon, therefore for the gland to have become vascularized and functionally active in its new situation*" ([@B44]), it was hypothesized that symptoms improved by absorption of the secretions of the donor gland ([@B47], [@B52]). Whereas, thyroid transplant was likely to provide uncertain quantities of the two hormones, T4 and T3, it could nevertheless be considered to be the earliest examples of a form of "combination therapy."

Trials of the first pharmacologic strategies included other combination therapies: intravenous/subcutaneous administration of thyroid extract was utilized by Murray to treat myxedema ([@B44], [@B53]--[@B55]), per oral thyroid extract ([@B56], [@B57]), or the consumption of raw or cooked thyroid gland ([@B55], [@B58], [@B59]). These strategies saw remarkable successes, "*the results are perfectly marvelous*" ([@B60]). Oral thyroid replacement strategies won favor as their successes were undeniable and without the morbidities and relapse rates associated with transplant. However, it was noted early on that there could be side effects of treatment: "*thyroid gland...is responsible for distressing and even alarming symptoms*," but the details were not fully described ([@B61]). Progress toward a modern thyroid transplant treatment modality is ongoing given that functional thyroid tissue can be generated from stem cells by over-expression of the thyroid transcription factors ([@B62]--[@B64]), in which case the field would have come full circle ([@B65]).

Thyroxine was crystallized in 1915 by Kendall ([@B66]), its chemical structure identified ([@B67]), and was administered successfully as an IV therapy by 1925 ([@B68]). This provided the basis for the development of synthetic LT4 ([@B69], [@B70]), which was shown to be efficacious in the treatment of myxedema ([@B71]) and in patients who failed to respond to desiccated thyroid treatment where clinical response was defined as BMR and restoration of ovulation/fertility ([@B72]). In 1952, serum T3 was discovered by Gross and Pitt-Rivers ([@B73], [@B74]). Serum PBI emerged as a diagnostic test and therapeutic marker, reflecting the combined amounts of circulating, protein-bound, T4 and T3. In the era prior to the availability of the TSH assay, this was the most specific diagnostic tool ([@B75]). However, PBI was limited in terms of monitoring a response to treatment as the "*concentration of the PBI associated with restoration of a normal metabolic state depends upon the particular thyroid hormone employed*" ([@B76]). For example, LT3 was reported as correcting BMR without much increase in PBI ([@B77]), whereas LT4 increased PBI sometimes to above the upper limit of the normal range ([@B78]), and combination LT4 + LT3 and desiccated thyroid had the advantage of normalizing PBI ([@B79]).

As such, mixtures of LT4 and LT3 administered concomitantly were proposed and developed, "*the ideal thyroid hormone preparation should combine* \[LT4 and LT3\] *in physiologic proportions to simulate the metabolic effects of endogenous thyroid hormone secretions*" ([@B80]). These investigators concluded that a mixture of 175 mcg LT4:50mcg LT3 was ideal because it optimized both BMR and PBI ([@B80]), but other investigators proposed ratios on the order of about 9:1 ([@B81]). Thus, despite the development of LT4, combination therapy via LT4 + LT3 or desiccated thyroid was still the preferred regimen ([@B3]).

Clinical trials were designed to assess efficacy and dose equivalency between the multiple forms of thyroid hormone replacement. Importantly, (i) these were not designed as superiority trials, (ii) outcomes assessed included normalization of PBI and/or BMR, and (iii) doses were dramatically higher than used today ([@B3]). Therefore, it is difficult to determine whether any thyrotoxic side effects were related to the type of the agent used or a consequence of its high dosage. For example, in studies utilizing doses of LT3 75--100 mcg/day, angina and congestive heart failure were observed ([@B82]); in another trial, palpitations, irritability, nervousness, dizziness, tremor, and perspiration were observed on LT4 (80 mcg) plus LT3 (20 mcg) daily ([@B83]).

Despite these concerns, it was noted that these thyrotoxic side effects were typically remediable by simple reduction in dosage ([@B82], [@B84]), so combination therapy, usually by desiccated thyroid, remained the preparation of choice ([@B85]) through the mid-1970\'s for the treatment of hypothyroidism ([@B3]). This preference was reinforced by the unique ability of desiccated thyroid to reproduce a normal PBI as compared with LT3 or LT4 monotherapies, making biochemical monitoring more straightforward ([Figure 1](#F1){ref-type="fig"}) ([@B7], [@B80]). In 1965, approximately four out of every five prescriptions for thyroid hormone were for natural preparations in the US ([@B86]).

![Historical Trends in the Treatment of Hypothyroidism. In the late 1800\'s--mid 1900\'s, combination therapy via thyroid transplant, thyroid feeding, thyroid extracts, thyroglobulin, or desiccated thyroid was preferred. Treatment was monitored by clinical response, basal metabolic rate (BMR), and/or serum protein-bound iodine (PBI). Thyrotoxic symptoms were prevalent in early clinical trials. In juxtaposition, levothyroxine (LT4) monotherapy to achieve normal serum TSH levels was adopted as the standard of care in the 1970\'s. It has become more recognized that patients on this regimen can have residual signs and symptoms of hypothyroidism. Thus, underscoring the need for new, physiologic thyroid replacement regimens with the goal to restore thyroid hormone signaling within all tissues. With the recognition that genetic polymorphisms may play a significant clinical role, personalized medicine will likely be integrated into future clinical trials and treatment regimens.](fendo-10-00446-g0001){#F1}

Prominent manufacturers of natural thyroid products including both desiccated thyroid ([@B87]) and thyroglobulin ([@B88]), boasted about their "*double standardization*" ([@B87]) methods to ensure "*unvarying metabolic activity*" ([@B88]) between batches; this included (i) chemical assessment of iodine content to adhere to the standards of the British or United States Pharmacopeia (BP or USP) as well as (ii) biologic activity assessed by change in oxygen consumption in treated guinea pigs ([@B89]) or its ability to reduce the size of animal goiters ([@B90]). Despite these efforts, clinicians remained rightfully concerned regarding inconsistencies in the potency of these tablets ([@B91]). Even as early as 1911, physicians understood that there was variability within natural thyroid preparations, "*there are probably some \[preparations of thyroid\] on the market that are inactive. It is only natural that the properties and activity of the gland should vary in different animals, according to their age and sex, and probably even according to their pasturage*" ([@B92]). Despite adherence to iodine content standards, some batches had varying potency ([@B76]), such that tablets contained nearly double potency, and others had almost no detectable metabolic activity ([@B93]). Also, humidity limited the shelf-life of desiccated tablets ([@B84]). There were reports of patients failing to respond to desiccated thyroid altogether as their tablets contained no active thyroid hormone ([@B94]--[@B96]). This led to claims that desiccated thyroid was dangerous and "*that its manufacture be abolished*" ([@B97]); it became viewed by many as "*obsolete*" as it "*possesses no uniquely desirable properties and should, therefore be retired to the place that it has earned in medical history*" ([@B98]). It was not until 1985 that the revision of the USP standard from iodine content to T3/T4 content established stable potency ([@B86]).

Transition Away From Combination Therapy {#s3}
========================================

Despite growing discontent with variable potency of natural thyroid products ([@B93]), as well as lowering in cost of LT4 such that the two treatments were approximately equivalent ([@B99]), physicians hesitated to use LT4 monotherapy, concerned that it could result in a relative T3 deficiency ([@B84], [@B91]). However, the landmark discovery of peripheral T4-to-T3 conversion in athyreotic humans by Braverman et al. obviated this concern ([@B9]) and provided the foundation for the hypothesis that LT4 could replace prohormone pool and the deiodinases would regulate availability of active T3 ([@B11]). This discovery had a major influence on the prescribing practices of physicians such that within about a decade there was a major transition toward LT4 as the first-line therapy in hypothyroidism ([@B3], [@B86], [@B90]).

The TSH RIA was developed by Utiger almost simultaneously ([@B8]). Clinicians were able to titrate therapy to achieve a serum TSH within the normal range as a specific marker of thyroid hormone replacement adequacy ([@B100]--[@B102]). This came with the caveat that early TSH assays were not able to distinguish between normal and low serum TSH levels ([@B103]). Thus, patients treated to a suppressed TSH (normal for that method) could only be differentiated through employment of a second test, the thyrotropin-releasing hormone (TRH) stimulation test, which could identify over-treated patients (suppressed TSH) by their subnormal response to exogenous TRH ([@B104]). For patients that were once treated with doses that normalized their symptoms, BMR, or PBI, the utilization of serum TSH (associated with the TRH stimulation test) revealed such doses to be typically supratherapeutic ([@B14], [@B103], [@B105], [@B106]). Whereas, prior to the institution of the TSH assay, typical maintenance doses of LT4 were in the 200--500 mcg/day range, doses were now typically closer to 100--150 mcg/day ([@B3], [@B103], [@B105], [@B106]).

Soon thereafter was the development of RIAs for measurement of serum T3 ([@B107], [@B108]) and T4 ([@B109]). With the availability of these assays, it was observed that LT4 could normalize both T4 and T3 levels at the expense of a high T4/T3 ratio. LT3, desiccated thyroid, thyroglobulin, and LT4 + LT3 combination all typically resulted in low or low-normal T4 values with usually elevated T3 levels ([@B90]). In particular, it was noted that desiccated thyroid resulted in a T3 peak occurring about 2--5 h after administration that corresponds to thyrotoxic symptoms in some patients ([@B99]). That a single daily dose of oral LT4 resulted in nearly seemingly physiologic, stable blood levels of T4 and T3 throughout the day ([@B107]) was understood to be a result of a steady rate of conversion of T4-to-T3 ([@B110], [@B111]). In less than a decade after discovery of peripheral T4-to-T3 conversion and with implementation of RIAs to specifically quantitate serum TSH, T4, and T3, normalization of TSH with LT4 became the new standard of care ([Figure 1](#F1){ref-type="fig"}) ([@B3], [@B112]). These findings left many clinicians advocating not only for LT4 to be the first-line therapy, but that patients previously treated with desiccated thyroid be transitioned to LT4 ([@B99]).

Defining "Euthyroidism" and Revisiting Combination Therapy {#s4}
==========================================================

Following the transition to LT4 monotherapy and reduction in replacement dose to achieve a normal TSH, clinicians noted several important differences in the ability of this regimen to normalize markers of hypothyroidism such as BMR, serum cholesterol, and patient satisfaction ([@B3]). In many LT4-treated hypothyroid patients with a normal TSH, the BMR remained at about −10% of that of normal controls ([@B113]). Whereas, LT4 treatment at doses that normalize BMR, can suppress the serum TSH ([@B90], [@B103], [@B105], [@B106], [@B114]). Recent investigations have confirmed that energy expenditure is only normalized in LT4 treatment at doses that suppress the serum TSH ([@B115]). Another study found that energy expenditure does not differ between groups treated with LT4 doses to result in either high-normal or low-normal serum TSH levels ([@B116]). Hypothyroidism is a secondary cause of dyslipidemia, typically manifesting in elevation of LDL and total cholesterol levels ([@B31]), however, it was noted that normalization of LDL in LT4-treated hypothyroid patients can require TSH-suppressive doses ([@B117], [@B118]). Complaints from dissatisfied patients treated with LT4 monotherapy at doses to normalize the serum TSH were often dismissed as unrelated to their thyroid condition ([@B119]), or attributed to non-compliance ([@B120]), as symptoms are non-specific and can overlap with other common conditions including menopause, depression, and chronic fatigue syndrome ([@B2]). However, LT4-treated patients display significant impairment in psychological well-being compared to controls of similar age and sex ([@B14]). To assess whether this was a result of trends toward lower doses of LT4, measures of well-being were tracked on various doses and it was found that the highest well-being is achieved at doses resulting in a suppressed TSH ([@B121]). However, such findings were not always reproducible ([@B122]). Indeed, it has been shown in a large population study that LT4-treated patients exhibit higher BMIs and take more statins and anti-depressants than TSH-matched, healthy controls ([@B15]); this association could have been impacted by confounding and thus further investigation is indicated to confirm these results ([@B15]). Thus, in LT4 monotherapy, defining euthyroidism as normal serum TSH has flaws as other clinical parameters may not be normalized.

Overtreatment associated with a low serum TSH, is associated with increased cardiovascular and skeletal risks ([@B1]), thus in the current guidelines a goal of therapy remains achievement of normal serum TSH levels ([Table 1](#T1){ref-type="table"}) ([@B1], [@B26], [@B27]). A small study found that patients perceived that their physicians were overly reliant on serum TSH levels and that this was a barrier to them receiving optimal care ([@B123]). Prescribing patterns have changed such that serum TSH level at time of initial treatment has been decreasing ([@B124], [@B125]) yet this may not improve quality of life or thyroid-related symptoms ([@B126]). Thus, reconciliation between optimization of patient outcomes without the increased risks of overtreatment remains a unique challenge in the field.

It should be noted that assessment and interpretation of serum T3 levels presents significant limitations as well due to (i) the difficulties accurately measuring serum free T3 with standard clinical lab assays ([@B18]), (ii) the fact that serum T3 levels may not fully represent intracellular T3 due to intracellular deiodination ([@B10]), and (iii) other non-thyroidal illnesses are known to result in low serum T3 ([@B1], [@B18]). In a study of 42 patients, assessment of serum T3 at baseline and during combination therapy did not predict positive, symptomatic response ([@B127]). Thus, the clinical utility of serum T3 measurements is unknown ([@B1]).

In a clinical trial of combination therapy with LT4 + LT3 to establish normal serum TSHs, there was improvement in psychological parameters ([@B19]). In another study comparing LT4 monotherapy to desiccated thyroid, in which both groups had a normal TSH, 48% of patients preferred desiccated thyroid over LT4 monotherapy (18.6% preferred LT4) and those patients preferring dessicated thyroid also experienced about 4 pound weight loss over the 16 week treatment period ([@B21]). Indeed, many clinical trials show subjective "preference" for combination therapy without positive objective results when utilizing quality of life and/or thyroid-specific questionnaires ([@B19], [@B21], [@B128], [@B129]). This suggests that these questionnaires may not be capturing the parameters improved by combination therapy, and opens yet another path for further research. Benefits with combination therapy have not been reproduced in all populations, and many studies fail to demonstrate superiority of combination therapy ([@B1], [@B14]). This may be related to the pharmacologic properties of available oral LT3 preparations. There are theoretical concerns about adverse events with LT3 treatment, but in one observational study over 17 years, there were no increased cardiovascular or skeletal risks ([@B130]).

Modern professional societies have synthesized their best practice guidelines for hypothyroidism. These guidelines have been evolving away from a universal approach with LT4 monotherapy ([@B23], [@B24], [@B131]) and toward an approach that accepts a therapeutic trial of combination therapy for select patients ([Table 1](#T1){ref-type="table"}) ([@B1], [@B26], [@B27]). In 1995, the American Thyroid Association (ATA) recommended LT4 monotherapy, and recommended against LT3 due to risk of iatrogenic thyrotoxicosis ([@B23]). In their conjoint guideline, the ATA and the American Association of Clinical Endocrinologists (AACE) stated that "*all physicians will treat clinical hypothyroidism with levothyroxine*" ([@B24]), and also recommended against combination therapy ([Table 1](#T1){ref-type="table"}). These recommendations were similarly upheld in the ATA/AACE guidelines in 2012 ([@B131]). The 1995, 2002, and 2012 guidelines all recommended normalization of serum TSH as the treatment goal ([Table 1](#T1){ref-type="table"}; [Figure 1](#F1){ref-type="fig"}) ([@B23], [@B24], [@B131]).

However, in 2012, the European Thyroid Association (ETA) published guidelines ([@B26]) in contrast to those of ATA/AACE ([@B131]). These ETA guidelines acknowledged that some LT4-treated patients with normal serum TSHs may have persistent symptoms based on increased verbalization from patient advocacy groups and supportive evidence from some clinical trials ([@B26], [@B128]). These guidelines also clearly documented hypotheses for treatment dissatisfaction among hypothyroid individuals: causes related to disease chronicity, associated autoimmune diseases, thyroid autoimmunity, inadequate LT4 dosing, and inadequacy of LT4 treatment modality ([@B26]). The acknowledgment of dissatisfaction among a significant proportion of individuals and documentation of possible etiologies to stimulate future research ([@B26]), seem to be in stark contrast to the previous paradigm of universal LT4 monotherapy ([Table 1](#T1){ref-type="table"}) ([@B23], [@B24], [@B131]). The ETA offered a second-line approach for these symptomatic individuals: using LT4 + LT3 combination therapy for select individuals in "carefully executed" therapeutic trials. The ATA then built upon these recommendations given the new evidence that polymorphisms in the deiodinases can be associated with differences in serum thyroid hormone levels ([@B132]) and acknowledgment that some LT4-treated individuals have relatively low serum T3 concentrations ([@B1], [@B16], [@B17], [@B133]--[@B135]). The ATA did note that there were inconsistent findings from clinical trials of combination therapy, thus superiority of combination therapy had not been established ([@B1]). Goals of therapy included normalization of serum TSH and "*to provide resolution of the patients\' symptoms and hypothyroid signs, including biological and physiologic markers of hypothyroidism*" ([@B1]). Although these markers were not well-defined, this represented a significant shift compared to prior ATA guidelines ([Table 1](#T1){ref-type="table"}) ([@B23], [@B131]). The British Thyroid Foundation likewise recommended therapeutic trial of LT4 + LT3 combination therapy to "*restore physical and psychological well-being"* ([@B27]). Despite consensus from these societies that LT4 monotherapy remain as first-line, a recent survey found that at least 58% of clinicians would prescribe a trial of combination therapy for specific clinical scenarios in which LT4-treated patients with normal serum TSH exhibited residual symptoms ([@B136]).

New Evidence May Justify Combination Therapy {#s5}
============================================

The importance of investigating the benefits associated with combination therapy in humans is highlighted by findings in an animal model of hypothyroidism. As in humans, LT4 monotherapy for athyreotic rats results in a high T4:T3 ratio at doses sufficient to normalize serum TSH levels ([@B29]). Yet, the brain, liver and skeletal muscle tissues of these LT4-treated animals exhibit markers of localized hypothyroidism ([@B29]), likely due the inability of LT4 monotherapy to restore tissue levels of T3 ([@B30]). This occurs as a direct consequence of the relatively high T4 concentration in these tissues: D2 downregulation is T4-mediated. In the hypothalamus, as a result of localized reduction in D2 ubiquitination, there is increased sensitivity to T4 levels, explaining the ability of the TSH to be normalized despite relatively lower levels of serum T3. Thus, only combination therapy with stable release LT4 + LT3 normalized all parameters of thyroid hormone homoeostasis ([@B29]) including serum and tissue T3 levels in rodents ([@B30]). In humans, LT4 monotherapy results in a high T4:T3 ratio ([@B15], [@B16], [@B120], [@B137]), thus underscoring the importance in establishing its clinical significance ([@B1], [@B18], [@B31], [@B138]). A large systematic review and meta-analysis of T3-dependent markers in hypothyroid humans treated with LT4 monotherapy, showed that LDL (3.31 ± 1.64 mg/dL) and total cholesterol (9.60 ± 3.55 mg/dL) remain higher in LT4-treated patients than healthy controls, despite normalization of serum TSH ([@B31]). The clinical significance of this difference in serum cholesterol remains to be determined, however this may justify well-designed clinical trials of combination therapy utilizing tissue-specific markers of thyroid status as outcome measures.

One factor that has been associated with response to combination therapy in multiple clinical trials is the Thr92Ala polymorphism in the type 2 deiodinase, where carriers can exhibit improved quality of life measures and preference for combination therapy ([@B20], [@B22]). This has led to the logical hypothesis that Thr92AlaD2 could be associated with localized and/or systemic hypothyroidism, yet results from clinical trials have not been consistently supportive ([@B139]--[@B141]). Multiple groups have demonstrated normal *in vitro* Thr92AlaD2 enzyme kinetics ([@B142], [@B143]), but other groups have found evidence of reduced enzymatic activity at the cellular and organism level ([@B144]). The Thr92AlaD2 protein has been found to disturb cellular physiology: it had a longer half-life, localized in the Golgi apparatus and significantly alter the transcriptome while stably expressed *in vitro* ([@B33]). In the same study, it was demonstrated that in the human temporal pole the transcriptome was similarly altered, resulting in a proposed 81-gene fingerprint of Thr92AlaD2 expression ([@B33]). An unexpected finding was that this transcriptome from human temporal pole samples shared expression patterns found in neurodegenerative diseases. Indeed, in a large cohort, African American carriers of Thr92AlaD2 exhibited about 30% greater risk of developing Alzheimer\'s disease ([@B32]), suggesting that the study of Thr92AlaD2 transcends the thyroid field. In a novel animal model of Thr92AlaD2 expression, there was evidence of ER stress and neurocognitive dysfunction; with administration of LT3 to animals with intact endogenous thyroids, the phenotype improved, bolstering support for the positive findings in many clinical trials ([@B34]). As the molecular basis for the Thr92AlaD2 observations is better characterized, it remains to be confirmed whether hypothyroid carriers may benefit from individualized therapies. If so, then the notion of personalized medicine, based on genotype, may define the future of management in hypothyroidism ([@B3]).

A slow-release oral form of LT3 was recently developed and applied in hypothyroid rats where it was found to provide stable, normal serum T3 levels ([@B145]). Results from human trials with this agent have yet to be determined, but this provides great hope that future high quality, randomized, controlled clinical trials will establish whether steady-dose LT3 + LT4 combination therapy is superior to LT4 monotherapy in terms of its ability to normalize all parameters of thyroid hormone homoeostasis, including tissue markers, mood, and cognition. Of course such trials would need to evaluate whether patients with the Thr92AlaD2 polymorphism, and other polymorphisms that could be relevant in thyroid hormone signaling, respond uniquely to treatments.

In conclusion, whereas combination therapy once dominated, this trend was largely abandoned in the 1970\'s due to evidence of iatrogenic thyrotoxicosis and concerns of consistency. In addition, a consequence of the availability of sensitive TSH assays was a dramatic reduction in thyroid hormone replacement dosage. Discovery of peripheral T4-to-T3 conversion provided initial physiologic justification for LT4 monotherapy. Clinical practice trended away from natural thyroid preparations and toward LT4 monotherapy given at doses to normalize the serum TSH. This transition was associated with the emergence of a population of patients with residual signs and symptoms of hypothyroidism and relatively lower serum T3 levels, despite normalization of serum TSH levels. New evidence that genetic polymorphisms may affect thyroid hormone signaling may substantiate objective evidence of residual localized and/or systemic hypothyroidism in a proportion of the population. The development of long acting formulations of LT3 to result in stable serum T3 levels may bolster development of a physiologic thyroid hormone replacement regimen to better mimic endogenous euthyroidism.
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